Shalu Sharma Kharkwal

Shalu Sharma Kharkwal

Auto-generated profile, based on publicly available information

Shalu Sharma Kharkwal

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Immunity
Verified
Journal Article
Open access
PAPooja Arora
Pooja Arora
ABAndres Baena
Andres Baena
KYKarl O.A. Yu
Karl O.A. Yu
NSNeeraj K. Saini
Neeraj K. Saini
SKShalu S. Kharkwal
Shalu S. Kharkwal
SPSteven A. Anthony Porcelli
Steven A. Anthony Porcelli
Many hematopoietic cell types express CD1d and are capable of presenting glycolipid antigens to invariant natural killer T cells (iNKT cells). However, the question of which cells are the principal presenters of glycolipid antigens in vivo remains controversial, and it has been suggested that this might vary depending on the structure of a particular glycolipid antigen. Here we have shown that a single type of cell, the CD8α(+) DEC-205(+) dendritic cell, was mainly responsible for capturing and presenting a variety of different glycolipid antigens, including multiple forms of α-galactosylceramide that stimulate widely divergent cytokine responses. After glycolipid presentation, these dendritic cells rapidly altered their expression of various costimulatory and coinhibitory molecules in a manner that was dependent on the structure of the antigen. These findings show flexibility in the outcome of two-way communication between CD8α(+) dendritic cells and iNKT cells, providing a mechanism for biasing toward either proinflammatory or anti-inflammatory responses.

1 March 2014 in Immunotherapy
Verified
Journal Article
Closed access
LCLeandro J Carreño
Leandro J Carreño
SKShalu Sharma Kharkwal
Shalu Sharma Kharkwal
SPSteven A. Anthony Porcelli
Steven A. Anthony Porcelli
NKT cells are a subpopulation of T lymphocytes with phenotypic properties of both T and NK cells and a wide range of immune effector properties. In particular, one subset of these cells, known as invariant NKT cells (iNKT cells), has attracted substantial attention because of their ability to be specifically activated by glycolipid antigens presented by a cell surface protein called CD1d. The development of synthetic α-galactosylceramides as a family of powerful glycolipid agonists for iNKT cells has led to approaches for augmenting a wide variety of immune responses, including those involved in vaccination against infections and cancers. Here, we review basic, preclinical and clinical observations supporting approaches to improving immune responses through the use of iNKT cell-activating glycolipids. Results from preclinical animal studies and preliminary clinical studies in humans identify many promising applications for this approach in the development of vaccines and novel immunotherapies.

5 July 2016 in Immunogenetics
Verified
Journal Article
Closed access
PDF file
SKShalu Sharma Kharkwal
Shalu Sharma Kharkwal
PAPooja Arora
Pooja Arora
SPSteven A. Anthony Porcelli
Steven A. Anthony Porcelli

25 September 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MVManjunatha M. Venkataswamy
Manjunatha M. Venkataswamy
TNTony W. Ng
Tony W. Ng
SKShalu S. Kharkwal
Shalu S. Kharkwal
LCLeandro J. Carreño
Leandro J. Carreño
AJAlison J. Johnson
Alison J. Johnson
SPSteven A. Anthony Porcelli
Steven A. Anthony Porcelli
Recombinant Mycobacterium bovis bacillus Calmette-Guèrin (rBCG) has been explored as a vector for vaccines against HIV because of its ability to induce long lasting humoral and cell mediated immune responses. To maximize the potential for rBCG vaccines to induce effective immunity against HIV, various strategies are being employed to improve its ability to prime CD8+ T cells, which play an important role in the control of HIV infections. In this study we adopted a previously described approach of incorporating glycolipids that activate CD1d-restricted natural killer T (NKT) cells to enhance priming of CD8+ T cells by rBCG strains expressing an SIV Gag antigen (rBCG-SIV gag). We found that the incorporation of the synthetic NKT activating glycolipid α-galactosylceramide (α-GC) into rBCG-SIV gag significantly enhanced CD8+ T cell responses against an immunodominant Gag epitope, compared to responses primed by unmodified rBCG-SIV gag. The abilities of structural analogues of α-GC to enhance CD8+ T cell responses to rBCG were compared in both wild type and partially humanized mice that express human CD1d molecules in place of mouse CD1d. These studies identified an α-GC analogue known as 7DW8-5, which has previously been used successfully as an adjuvant in non-human primates, as a promising compound for enhancing immunogenicity of antigens delivered by rBCG.vectors. Our findings support the incorporation of synthetic glycolipid activators of NKT cells as a novel approach to enhance the immunogenicity of rBCG-vectored antigens for induction of CD8+ T cell responses. The glycolipid adjuvant 7DW8-5 may be a promising candidate for advancing to non-human primate and human clinical studies for the development of HIV vaccines based on rBCG vectors.

7 August 2018 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
NVNatacha Veerapen
Natacha Veerapen
SKShalu Sharma Kharkwal
Shalu Sharma Kharkwal
PJPeter Jervis
Peter Jervis
VBVeemal Bhowruth
Veemal Bhowruth
ABAmareeta K. Besra
Amareeta K. Besra
SPSteven A. Porcelli
Steven A. Porcelli

1 January 2016 in Chemistry and Physics of Lipids
Verified
Journal Article
Open access
PAPooja Arora
Pooja Arora
SKShalu S. Kharkwal
Shalu S. Kharkwal
TNTony W. Ng
Tony W. Ng
SKShajo Kunnath-Velayudhan
Shajo Kunnath-Velayudhan
NSNeeraj K. Saini
Neeraj K. Saini
SPSteven A. Anthony Porcelli
Steven A. Anthony Porcelli
Invariant natural killer T (iNKT) cells recognize glycolipid antigens presented by CD1d, an antigen presenting protein structurally similar to MHC class I. Stimulation of iNKT cells by glycolipid antigens can induce strong immune responses in vivo, with rapid production of a wide variety of cytokines including those classically associated with either T helper type 1 (Th1) or type 2 (Th2) responses. Alterations in the lipid tails or other portions of CD1d-presented glycolipid ligands can bias the iNKT response towards production of predominantly Th1 or Th2 associated cytokines. However, the mechanism accounting for this structure-activity relationship remains controversial. The Th1-biasing glycolipids have been found to consistently form complexes with CD1d that preferentially localize to plasma membrane cholesterol rich microdomains (lipid rafts), whereas CD1d complexes formed with Th2-biasing ligands are excluded from these microdomains. Here we show that neutralization of endosomal pH enhanced localization of CD1d complexes containing Th2-biasing glycolipids to plasma membrane lipid rafts of antigen presenting cells (APC). Transfer of APCs presenting these "stabilized" CD1d/αGC complexes into mice resulted in immune responses with a more prominent Th1-like bias, characterized by increased NK cell transactivation and interferon-γ production. These findings support a model in which low endosomal pH controls stability and lipid raft localization of CD1d-glycolipid complexes to regulate the outcome of iNKT cell mediated responses.